Skip to main content

Advertisement

SpringerLink
Log in

Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma

  • Clinical Study - Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

According to World Health Organization (WHO) and Daumas-Duport grading systems, progression of oligodendrogliomas (ODGs) to a higher grade (WHO grade III, grade B) is associated with increased angiogenesis. Based on multivariate assessment of molecular, pathological, and radiological parameters, we further assessed the influence of tumor angiogenesis on tumor progression and patient survival. Patients with a diagnosis of ODG, consecutively treated in a single institution, were reviewed and reclassified according to WHO and Daumas-Duport grading systems. MRI scans were reviewed to assess contrast enhancement and necrosis. Tissue sections were used for pathology review and to evaluate immunostaining of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (VEGF-R), Ki-67, and CD34. Multivariate analysis was performed to assess the impact of tumor angiogenesis-related pathological and radiological factors on patient survival. One hundred thirty-four patients with pure ODG were included in this study. Multivariate analysis identified four independent poor prognostic factors: necrosis, absence of seizure, increased vascularization, and age >55 years. A subgroup of patients with tumor necrosis, increased vascularization, and absence of seizures had a significantly worse outcome than predicted, with a median overall survival of 14.2 months. VEGF expression was significantly higher in this subgroup and correlated with disease progression regardless of histologic grade. Based on the presence of radiological or pathological necrosis, contrast enhancement or endothelial hyperplasia, and absence of seizures, a high risk group of ODG can be identified with significantly worse overall survival. Also, VEGF over-expression in ODG constitutes an early marker for predicting tumor progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Daumas-Duport C, Varlet P, Tucker ML et al (1997) Oligodendrogliomas. Part I: patterns of growth, histological diagnosis, clinical and imaging correlations: a study of 153 cases. J Neurooncol 34:37–59

    Article  CAS  PubMed  Google Scholar 

  2. Shaw EG, Scheithauer BW, O’Fallon JR et al (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434

    Article  CAS  PubMed  Google Scholar 

  3. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975–2004, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER web site, 2007

  4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714

    Article  CAS  PubMed  Google Scholar 

  5. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial. J Clin Oncol 24:2715–2722

    Article  PubMed  Google Scholar 

  6. Quon H, Abdulkarim B (2008) Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev, Issue 2. Art. No.: CD007104. DOI: 10.1002/14651858.CD007104

  7. Schiffer D, Dutto A, Cavalla P et al (1999) Prognostic factors in oligodendroglioma. Can J Neurol Sci 24:313–319

    Google Scholar 

  8. Saito A, Nakazato Y (1999) Evaluation of malignant features in oligodendroglial tumors. Clin Neuropathol 18:61–73

    CAS  PubMed  Google Scholar 

  9. Burger PC, Rawlings CE, Cox EB, McLendon RE, Schold SC Jr, Bullard DE (1987) Clinicopathologic correlations in the oligodendroglioma. Cancer 59:1345–1352

    Article  CAS  PubMed  Google Scholar 

  10. Celli P, Nofrone I, Palma L et al (1994) Cerebral oligodendroglioma: prognostic factors and life history. Neurosurgery 35:1018–1034

    Article  CAS  PubMed  Google Scholar 

  11. Fortin D, Cairncross GJ, Hammond RR (1999) Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment. Neurosurgery 45:1279–1291

    Article  CAS  PubMed  Google Scholar 

  12. Giannini C, Scheithauer BW, Weaver AL et al (2001) Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 60:248–262

    CAS  PubMed  Google Scholar 

  13. Vaquero J, Zurita M, Morales C et al (2001) Prognostic significance of the endothelial surface in low-grade resected oligodendrogliomas. Br J Neurosurg 15:247–260

    Article  CAS  PubMed  Google Scholar 

  14. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4–6

    Article  CAS  PubMed  Google Scholar 

  15. Daumas-Duport C, Tucker ML, Kolles H et al (1997) Oligodendrogliomas. Part II: a new grading system based on morphological and imaging criteria. J Neurooncol 34:61–78

    Article  CAS  PubMed  Google Scholar 

  16. Brem S, Cotran R, Folkman J (1972) Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48:347–356

    CAS  PubMed  Google Scholar 

  17. Kleihues P, Cavenee WK, eds (2000). Pathology and genetics: tumors of the nervous system. In: WHO classification of tumors. Lyon (France): IARC press, 56–61

  18. Engelhard HH, Stelea A, Cochran EJ (2002) Oligodendroglioma: pathology and molecular biology. Surg Neurol 58:111–117

    Article  PubMed  Google Scholar 

  19. LeBlanc M, Crowley J (1992) Relative risk trees for censored survival data. Biometrics 48:411–425

    Article  CAS  PubMed  Google Scholar 

  20. Leighton C, Fisher B, Bauman G et al (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15:1294–1301

    CAS  PubMed  Google Scholar 

  21. Plate KH, Breier G, Weich HA, Risau W (1992) Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845–848

    Article  CAS  PubMed  Google Scholar 

  22. Miller CR, Dunham CP, Scheithauer BW, Perry A (2006) Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 24(34):5419–5426

    Article  PubMed  Google Scholar 

  23. Kouwenhoven MC, Gorlia T, Kros J, et al. (2009). Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology. 2009 February 17

  24. Bigner SH, Matthews MR, Rasheed BK et al (1999) Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization. Am J Pathol 155:375–386

    CAS  PubMed  Google Scholar 

  25. Smith JS, Perry A, Borell TJ et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645

    CAS  PubMed  Google Scholar 

  26. McDonald JM, See SJ, Tremont IW et al (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477

    Article  CAS  PubMed  Google Scholar 

  27. Bortolotto S, Chiado-Piat L, Cavalla P et al (2000) CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 88:554–567

    Article  CAS  PubMed  Google Scholar 

  28. Perry A, Aldape KD, George DH, Burger PC (2004) Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendrogliomas. Cancer 101:2318–2326

    Article  PubMed  Google Scholar 

  29. Chan AS, Leung SY, Wong MP et al (1998) Expression of vascular endothelial growth factor and its receptors in the anaplastic progression of astrocytoma, oligodendroglioma, and ependymoma. Am J Surg Pathol 22:816–826

    Article  CAS  PubMed  Google Scholar 

  30. Abdulrauf SI, Edvardsen K, Ho KL et al (1998) Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurg 88:513–520

    Article  CAS  PubMed  Google Scholar 

  31. Pietsch T, Valter MM, Wolf HK et al (1997) Expression and distribution of vascular endothelial growth factor protein in human brain tumors. Acta Neuropathol 93:109–117

    Article  CAS  PubMed  Google Scholar 

  32. Christov C, Adle-Biassette H, Le Guerinel C et al (1998) Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the vasculature of oligodendrogliomas. Neuropathol Appl Neurobiol 24:29–35

    Article  CAS  PubMed  Google Scholar 

  33. Godfraind C, Rousseau E, Ruchoux MM et al (2003) Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas. Neuropathol Appl Neurobiol 29:462–471

    Article  CAS  PubMed  Google Scholar 

  34. Harada H, Nakagawa K, Iwata S et al (1999) Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res 59:3783–3789

    CAS  PubMed  Google Scholar 

  35. Jen J, Harper JW, Bigner SH et al (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353–6358

    CAS  PubMed  Google Scholar 

  36. Varlet P, Guillamo JS, Nataf F et al (2000) Vascular endothelial growth factor expression in oligodendrogliomas: a correlative study with Sainte-Anne malignancy grade, growth fraction and patient survival. Neuropathol Appl Neurobiol 26:379–389

    Article  CAS  PubMed  Google Scholar 

  37. Louis DN, Holland EC, Cairncross JG (2001) Glioma classification: a molecular reappraisal. Am J Pathol 159:779–786

    CAS  PubMed  Google Scholar 

  38. Reifenberger J, Reifenberger G, Liu L et al (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190

    CAS  PubMed  Google Scholar 

  39. Burger PC, Minn AY, Smith JS et al (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842–853

    Article  CAS  PubMed  Google Scholar 

  40. Cairncross JG, Ueki K, Zlatescu MC et al (1999) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479

    Article  Google Scholar 

  41. Thiessen B, Maguire JA, McNeil K et al (2003) Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity. J Neurooncol 64:271–278

    Article  PubMed  Google Scholar 

  42. Hashimoto N, Murakami M, Takahashi Y et al (2003) Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p. Cancer 97:2254–2261

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Cross Cancer Institute & University of Alberta, 11560 University Avenue, Edmonton, AB, T6G 1Z2, Canada

    H. Quon & B. Abdulkarim

  2. Department of Oncology, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805, Villejuif, France

    A. Hasbini & B. Abdulkarim

  3. Department of Statistic and Clinical Research, Schering-Plough, 92 rue Baudin, 92 307, Levallois-Perret Cedex, France

    J. Cougnard & L. Djafari

  4. Department of Pathology, Hôpital Kremlin Bicetre and Universite Paris XI, 78, rue du General-Leclerc, 94275, Le Kremlin-Bicetre, France

    C. Lacroix

Authors
  1. H. Quon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hasbini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Cougnard
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Djafari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Lacroix
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Abdulkarim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Abdulkarim.

Additional information

Harvey Quon and Ali Hasbini contributed equally as first authors.

Study was accepted for “poster viewing” at the 50th ASTRO annual meeting, September 21–25, 2008, Boston, Massachusetts.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quon, H., Hasbini, A., Cougnard, J. et al. Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma. J Neurooncol 96, 277–285 (2010). https://doi.org/10.1007/s11060-009-9961-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9961-x

Keywords

Search

Navigation